The article Review of Current Thoracic Endografts with or Pending FDA Approval by Wang and Milner is a timely current-status report on TEVAR technologies, and constitutes an excellent foundation for this issue’s editorial. While aneurysms and dissections predominate, thoracic aortic pathologies are diverse and of multiple etiologies. Put all together, the total number of patients may approximate, if not surpass, AAA volumes. Surgical repair has been the acknowledged standard of care for a long time. But, while treatment outlook has improved over the past 20 years, largely as a result of adva

Acute coronary syndromes (ACS) and ischemic strokes develop suddenly and often unpredictably in patients with vascular disease. In the majority of patients, these clinical scenarios result from either rupture of a thin-cap fibroatheroma or superficial erosion of an atheroma.¹ An intraluminal thrombus then forms on the damaged lesion, possibly embolizing and resulting in decreased blood flow within the artery leading to ischemia and clinical instability. In the coronary circulation, the result of thrombus and embolus formation is myocardial ischemia, infarction, or death, while in th

Introduction
Most patients described in the literature with spontaneous rectus sheath hematomas are on a form of medical anticoagulant therapy or have a bleeding diathesis.^1–3 The indication for angiography includes persistent bleeding and hemodynamic instability, despite reversal of anticoagulation.¹⁰ The majority of these indicated cases were treated by transarterial embolization (TAE).^1,2,4,5

Case 1
A 67-year-old male presented to the emergency department with a swollen left lower limb and confirmed deep venous thrombosis (DVT) follow